# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338244
Filing Date
2026-08-06
Accepted
2026-08-06 16:31:10
Documents
64
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | xene-20260630.htm iXBRL | 10-Q | 2848872
2 | EX-31.1 | xene-ex31_1.htm | EX-31.1 | 17013
3 | EX-31.2 | xene-ex31_2.htm | EX-31.2 | 17009
4 | EX-32.1 | xene-ex32_1.htm | EX-32.1 | 12359
5 | EX-32.2 | xene-ex32_2.htm | EX-32.2 | 11792
| Complete submission text file | 0001193125-26-338244.txt |  | 10151852

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | xene-20260630.xsd | EX-101.SCH | 955487
68 | EXTRACTED XBRL INSTANCE DOCUMENT | xene-20260630_htm.xml | XML | 2079229

Mailing Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada
Business Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36687 | Film No.: 261249722
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)